Innate Pharma and AstraZeneca announce global co-development and commercialisation agreement for IPH2201 in immuno-oncology
Innate Pharma and Sanofi collaborate on next generation antibody-drug conjugates using Innate’s site-specific conjugation technology
DSMB recommends continuation of effiKIR trial with two arms
Innate Pharma to hold its Annual General Meeting of Shareholders on April 27, 2015 and the release of its reference document (in french)
Number of shares and voting rights of Innate Pharma as at March 19, 2015
Innate Pharma collaborates with NCIC Clinical Trials Group on the phase I/II trial of IPH2201 in ovarian cancer
Annual results 2014: stronger cash position and expanded clinical portfolio
Number of shares and voting rights of Innate Pharma as at December 31, 2014
Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
First Phase II trial with IPH2201 open in head and neck cancer
